Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study

Completed · Not applicable

Conditions studied: Aortic Aneurysm, Contrast Induced Nephropathy, Aortic and Arterial Anomalies

In brief

The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality. The hypothesis is that there is no difference in image quality using ultra-low dose contrast in CTA exams compared to routine, standard of care dose exams.

Key facts

Study ID

NCT02669784

Run by

Milton S. Hershey Medical Center

People needed

34

Starts

2016-02-01

Expected to finish

2018-11-01

Last updated by the study team

2019-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any adult patient scheduled for a computed tomographic arteriogram (CTA) of the chest or chest, abdomen and pelvis who had undergone a prior CTA performed with the standard contrast dose (100 mL) at this institution will be included in the study
• The follow-up scan will be routine standard of care, no emergency imaging patient will be approached for this research

You may not qualify if…

• Patients with no prior CTA imaging for comparison
• Any pediatric patient (age <18)
• BMI >40
• Inability to follow instructions
• Allergy to intravenous contrast
• GFR less than 30 mL/min/1.73 m2

Where it is running

• Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.